tki/io comparison: lenvatinib/pembrolizumab vs cabozantinib/nivolumab vs axitinib/pembrolizumab
Published 1 year ago • 955 plays • Length 8:07Download video MP4
Download video MP3
Similar videos
-
8:15
choosing an io/tki doublet for rcc patients: efficacy data, dosing, and more
-
8:50
comparison of frontline renal cell carcinoma treatment options
-
10:06
lenvatinib and pembrolizumab compared to sunitinib for advanced renal cell carcinoma
-
4:40
pembrolizumab plus axitinib in the second-line and beyond for mrcc
-
4:49
pembrolizumab plus axitinib and the future of further-line mrcc treatments
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
3:35
checkmate-9er discussion: depth of response with first-line cabozantinib/nivolumab
-
3:26
extended follow-up from a trial of pembrolizumab plus axitinib for advanced renal cell carcinoma
-
38:09
understanding and working with new immunotherapeutic and targeted management models in advanced rcc
-
4:22
cabozantinib in combination w/ nivolumab and ipilimumab of imdc intermediate or poor risk signif...
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
55:12
selecting and sequencing targeted and immunotherapy regimens for patients with rcc
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
4:23
second-line treatment options for rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
1:28
comparing io/tki and tki monotherapy for kidney cancer
-
32:46
lenvatinib pembrolizumab in rcc, the clear trial with karine tawagi
-
7:18
who is the appropriate rcc patient to receive combination ipilimumab/nivolumab?